ArticleScientific reports2025
Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Curcumin (Cur), quercetin (Que), and piperine (Pip) are well-known plant-derived compounds with diverse pharmacological activities and health benefits. However, their clinical application is limited due to hydrophobicity and poor bioavailability. Polylactic-co-glycolic acid nanoparticles(PLGA NPs) provide efficient drug loading and sustained release, making them an ideal platform for controlled drug delivery. Cur, Que, and Pip co-loaded PLGA NPs (Cur-Que-Pip-PLGA NPs) were prepared using the emulsification-solvent evaporation method. Their physicochemical properties were characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), dynamic light scattering (DLS),and high-performance liquid chromatography (HPLC). Biocompatibility was assessed through the CCK-8 cytotoxicity assay and Calcein AM/PI cell viability staining. Antimicrobial activity was investigated via the agar diffusion method. The average particle size of Cur-Que-Pip-PLGA NPs was 210.6 ± 0.22 nm, with a zeta potential of -8.57 ± 1.16 mV and a polydispersity index (PDI) of 0.186 ± 0.010. The encapsulation efficiencies of Cur, Que, and Pip were 97.1%, 95.5%, and 45.5%, respectively. The NPs were spherical with smooth surfaces. In vitro studies revealed that the cumulative release of Cur-Que-Pip-PLGA NPs in PBS after 96 h of sustained release was 26.9%, 57.5%, and 98%, respectively. In contrast, the cumulative release of free Cur, Que, and Pip after only 8 h of sustained release reached 92.1%, 94.8%, and 96.6%, respectively. This comparison highlights the significant slow-release effect of PLGA NPs. The NPs exhibited excellent stability at 25 ± 3°C for 14 days. The results of the CCK-8 cytotoxicity assay and Calcein AM/PI cell death staining indicated that Cur-Que-Pip-PLGA NPs exhibited good biocompatibility with RAW264.7, BMSC, and MC3T3 cells, with no significant cytotoxic effects. Agar diffusion method confirmed its good antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Cur-Que-Pip-PLGA NPs demonstrate excellent biocompatibility, controlled release, and antimicrobial properties, suggesting potential for improving the therapeutic performance of hydrophobic compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.